Literature DB >> 12922114

Development of immune response that protects mice from viral pneumonitis after a single intranasal immunization with influenza A virus and nanoemulsion.

Andrzej Myc1, Jolanta F Kukowska-Latallo, Anna U Bielinska, Peter Cao, Piotr P Myc, Katarzyna Janczak, Tracy R Sturm, Michael S Grabinski, Jeffrey J Landers, Katherine S Young, Jennifer Chang, Tarek Hamouda, Michal A Olszewski, James R Baker.   

Abstract

Nanoemulsion, a water-in-oil formulation stabilized by small amounts of surfactant, is non-toxic to mucous membranes and produces biocidal activity against enveloped viruses. We evaluated nanoemulsion as an adjuvant for mucosal influenza vaccines. Mice (C3H/HeNHsd strain) were vaccinated intranasally with 5 x 10(5) plaque forming units (pfu) of influenza A virus (Ann Arbor/6/60 strain) and a nanoemulsion mixture. The mice were challenged on day 21 after immunization with an intranasal lethal dose of 2 x 10(5) pfu of virus. Animals vaccinated with the influenza A/nanoemulsion mixture were completely protected against infection, while animals vaccinated with either formaldehyde-killed virus or nanoemulsion alone developed viral pneumonitis and died by day 6 after the challenge. Mice vaccinated with virus/nanoemulsion mixture had rapid cytokine responses followed by high levels of specific anti-influenza immunoglobulin G (IgG) and immunoglobulin A (IgA) antibodies. Specificity of the immune response was confirmed by assessment of the proliferation and cytokine production in splenocytes. This paper demonstrates that nanoemulsion can be employed as a non-toxic mucosal adjuvant for influenza virus vaccine.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12922114     DOI: 10.1016/s0264-410x(03)00381-5

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  32 in total

Review 1.  Induction of Th17 cellular immunity with a novel nanoemulsion adjuvant.

Authors:  Anna U Bielinska; Michele Gerber; Luz P Blanco; Paul E Makidon; Katarzyna W Janczak; Michael Beer; Benjamin Swanson; James R Baker
Journal:  Crit Rev Immunol       Date:  2010       Impact factor: 2.214

Review 2.  Drug targeting to infectious diseases by nanoparticles surface functionalized with special biomolecules.

Authors:  Shyam Sundar; Vijay Kumar Prajapati
Journal:  Curr Med Chem       Date:  2012       Impact factor: 4.530

3.  Fourth International Conference: Modern Vaccines/Adjuvants Formulation--Impact on Future Development: May 15-17 2013, CHUV, Lausanne, Switzerland.

Authors:  Emmanuel Tupin
Journal:  Hum Vaccin Immunother       Date:  2013-07-29       Impact factor: 3.452

4.  Induction of immune response to the 17 kDa OMPA Burkholderia cenocepacia polypeptide and protection against pulmonary infection in mice after nasal vaccination with an OMP nanoemulsion-based vaccine.

Authors:  P E Makidon; J Knowlton; J V Groom; L P Blanco; J J LiPuma; A U Bielinska; J R Baker
Journal:  Med Microbiol Immunol       Date:  2009-12-06       Impact factor: 3.402

5.  Nanoemulsion-based mucosal adjuvant induces apoptosis in human epithelial cells.

Authors:  Beata U Orzechowska; Jolanta F Kukowska-Latallo; Alexa D Coulter; Zsuzsanna Szabo; Andrzej Gamian; Andrzej Myc
Journal:  Vaccine       Date:  2015-03-25       Impact factor: 3.641

6.  Distinct pathways of humoral and cellular immunity induced with the mucosal administration of a nanoemulsion adjuvant.

Authors:  Anna U Bielinska; Paul E Makidon; Katarzyna W Janczak; Luz P Blanco; Benjamin Swanson; Douglas M Smith; Tiffany Pham; Zsuzsanna Szabo; Jolanta F Kukowska-Latallo; James R Baker
Journal:  J Immunol       Date:  2014-02-14       Impact factor: 5.422

7.  Nanoemulsion nasal adjuvant W₈₀5EC induces dendritic cell engulfment of antigen-primed epithelial cells.

Authors:  Andrzej Myc; Jolanta F Kukowska-Latallo; Douglas M Smith; Crystal Passmore; Tiffany Pham; Pamela Wong; Anna U Bielinska; James R Baker
Journal:  Vaccine       Date:  2012-12-25       Impact factor: 3.641

8.  In vitro activities of a novel nanoemulsion against Burkholderia and other multidrug-resistant cystic fibrosis-associated bacterial species.

Authors:  John J LiPuma; Sivaprakash Rathinavelu; Bridget K Foster; Jordan C Keoleian; Paul E Makidon; Linda M Kalikin; James R Baker
Journal:  Antimicrob Agents Chemother       Date:  2008-10-27       Impact factor: 5.191

9.  Characterization of stability and nasal delivery systems for immunization with nanoemulsion-based vaccines.

Authors:  Paul E Makidon; Shraddha S Nigavekar; Anna U Bielinska; Nicholas Mank; Abhishek M Shetty; Julie Suman; Jessica Knowlton; Andrzej Myc; Trent Rook; James R Baker
Journal:  J Aerosol Med Pulm Drug Deliv       Date:  2010-04       Impact factor: 2.849

10.  Nanoemulsion W805EC improves immune responses upon intranasal delivery of an inactivated pandemic H1N1 influenza vaccine.

Authors:  Subash C Das; Masato Hatta; Peter R Wilker; Andrzej Myc; Tarek Hamouda; Gabrielle Neumann; James R Baker; Yoshihiro Kawaoka
Journal:  Vaccine       Date:  2012-09-16       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.